Abstract
Uterine carcinosarcoma (UCS) is a rare and highly malignant subtype of endometrial cancer. Paclitaxel and carboplatin therapy showed promising efficacy, but chemotherapy options are still limited. Human epidermal growth factor receptor 2 (HER2) expression was detected in 20-50% of UCS in previous studies. Hence, we conducted a clinical trial to assess the efficacy of trastuzumab deruxtecan (T-DXd) which was reported to be effective across HER2-positive cancers.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
